Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trials Optional)
ID: 350901Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $500K

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/350901

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-054.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity for High Impact Specialized Innovation Programs in Clinical and Translational Science, aimed at enhancing the capabilities and resources of Clinical and Translational Science Awards (CTSA) Program Hubs. This initiative seeks to address critical gaps and barriers in clinical and translational research, promoting innovative solutions that can lead to improved health outcomes. Eligible applicants, primarily UM1 CTSA hubs, can propose projects with budgets up to $500,000 per year for a duration of up to five years, with the first application deadline set for December 12, 2023. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-054.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-054-Full-Announcement.html
    PAR-24-054.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), announces a funding opportunity for High Impact Specialized Innovation Programs in Clinical and Translational Science. This initiative aims to support unique capabilities and resources within Clinical and Translational Science Awards (CTSA) Program Hubs, addressing key gaps and barriers in the field to enhance research efficiency and expedite health benefits from biomedical discoveries. Applications can propose up to five years of funding with budgets not exceeding $500,000 per year. Eligible organizations must be the primary UM1 CTSA hubs, and collaborative projects across CTSA hubs are encouraged. Key submission dates are outlined, with the earliest application due date on December 12, 2023. Applicants must provide specific plans for milestone tracking and sustainability beyond the grant period, ensuring alignment with the NCATS's strategic goals. The review process will assess the significance, innovation, approach, and the expertise of investigators involved. Overall, this funding opportunity seeks to bolster clinical and translational research that leads to improved health outcomes through innovative solutions.
    Similar Opportunities
    Clinical and Translational Science Award (UM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the Clinical and Translational Science Award (CTSA) Program, aimed at enhancing clinical and translational research through collaborative partnerships. This initiative invites applications for hubs that will focus on improving the efficiency of clinical translation, addressing health disparities, and fostering innovative research methodologies, with a particular emphasis on community engagement and workforce development. Successful applicants, which may include higher education institutions and nonprofit organizations, are expected to outline strategic management and demonstrate strong leadership, with projects capped at seven years and a submission deadline of September 28, 2027. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the funding opportunity page at https://grants.nih.gov/grants/guide/pa-files/PAR-24-272.html.
    Notice of Intent to Publish a Notice of Funding Opportunity for the Re-Issue of PAR-21-293 - Clinical and Translational Science Award (UM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to reissue a Notice of Funding Opportunity (NOFO) for the Clinical and Translational Science Award (CTSA) Program, aimed at establishing hubs that will contribute to a national consortium focused on accelerating the delivery of treatments to patients through advancements in clinical and translational science. This initiative is designed to foster meaningful collaborations and responsive projects among eligible applicants, which include various organizations and institutions. The anticipated NOFO is expected to be published in Summer 2024, with applications due by January 2025, and the estimated award date is set for December 16, 2025. Interested parties should prepare for the upcoming application process as no cost-sharing or matching is required for this cooperative agreement funding opportunity.
    Notice of Intent to Re-issue PAR-22-167 - Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to re-issue the Notice of Funding Opportunity Announcement (PAR-22-167) for the Clinical and Translational Science Award (CTSA) Program, specifically the Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional). This funding opportunity aims to foster meaningful collaborations and innovative projects in clinical and translational science, with no cost-sharing or matching requirements for eligible applicants, which include for-profit organizations. The estimated total program funding is $5 million, with an award ceiling of $650,000, and the NOFO is expected to be published in Fall 2024, with applications due in Winter 2025. Interested parties should prepare for the anticipated timeline, as the estimated project start date is December 1, 2025, and further details can be found on the CCIA webpage.
    Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program, designated as R03 Clinical Trial Optional. This funding opportunity aims to support KL2/K12 scholars and recipients of diversity and re-entry supplements in their transition to independent research roles by funding small, innovative, self-contained projects in translational science, with a maximum budget of $50,000 per year over a two-year period. The initiative is designed to enhance the capabilities of emerging researchers in addressing inefficiencies in translating research into clinical applications, engaging underrepresented populations, and improving data accessibility through innovative technologies. Applications will be accepted starting January 19, 2024, with multiple deadlines leading up to October 20, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    IDeA Clinical and Translational Research Network (CTR-N) Award (P50 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the IDeA Clinical and Translational Research Network (CTR-N) Award, a federal grant aimed at enhancing clinical and translational research capacity in IDeA-eligible states and jurisdictions. This initiative seeks to develop infrastructure and human resources necessary for addressing health challenges, strengthen research competitiveness, and foster collaboration among participating organizations. The program emphasizes addressing health disparities and requires applicants to demonstrate collaborative capacity, submit an Overall Plan detailing healthcare concerns and research goals, and include a Plan for Enhancing Diverse Perspectives. The award ceiling is set at $1,300,000, with applications due by October 9, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-241.html.
    Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp Clinical Trial NOT Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), in collaboration with the Centers for Disease Control and Prevention (CDC), has announced the Innovation Corps (I-Corps) at NIH Program, aimed at enhancing the commercialization of biomedical innovations from Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase I projects. This program provides administrative supplement awards to eligible small business concerns, facilitating entrepreneurship training and assisting teams in refining their commercialization strategies through customer discovery activities over an eight-week course. With a total funding pool of up to $2.64 million available for up to 48 awards, individual grants are capped at $55,000, and applications must be submitted by January 31, 2025. Interested applicants are encouraged to contact NIH Grants Information at grantsinfo@nih.gov for further guidance before applying.
    NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Notice of Funding Opportunity (NOFO) for the NIAID Clinical Trial Implementation Cooperative Agreement (U01), aimed at supporting high-risk clinical trials that enhance the understanding of human diseases. This funding opportunity encourages applications for investigator-initiated, milestone-driven clinical trials, with each application permitted to propose only one clinical trial that must demonstrate a hypothesis-driven approach. The initiative emphasizes the importance of mechanistic studies within clinical trials and requires a robust plan for managing trial complexity and participant safety. Interested applicants can find additional details and guidelines at the provided NIH link, with the earliest submission date set for April 12, 2024, and the application deadline on January 13, 2027. For inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    IDeA Clinical and Translational Research Development (CTR-D) Award (P20-Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the IDeA Clinical and Translational Research Development (CTR-D) Award (P20-Clinical Trial Optional) to enhance clinical and translational research capabilities in IDeA-eligible states. This funding opportunity aims to strengthen workforce development and improve infrastructure in health research organizations that typically have limited capacities for such research, with a focus on building research capacity and fostering collaboration within the community. Each organization can submit one application with a budget not exceeding $1.5 million over a maximum project period of five years, and successful applicants must address various cores including Administrative, Professional Development, Community Engagement, Research Design/Compliance, and Health Research, while also emphasizing diversity and inclusion in research. Interested applicants can find more information and submit their applications through the NIH ASSIST system or Grants.gov, with the application deadline set for October 9, 2025.
    Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required), inviting applications for long-term clinical trials lasting 6 or 7 years. These trials must be hypothesis-driven, aligned with NIH's research mission, and include clearly defined objectives and milestone planning to monitor progress. This initiative emphasizes the importance of extended clinical trials in advancing critical biomedical research, with no specific budget limits but requiring justification based on project needs. Interested applicants must consult with NIH staff prior to submission, adhere to new application forms and data sharing policies, and submit their applications by January 13, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-084.html.
    Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Center for Advancing Translational Sciences (NCATS), has announced the Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) funding opportunity. This grant program aims to support early-stage, high-risk exploratory research focused on developing innovative technologies that address barriers in therapeutic development, rather than targeting specific diseases or clinical trials. The initiative is designed to expedite the discovery and delivery of treatments, diagnostics, and devices to patients by fostering innovative research that can attract industry collaboration and additional funding. Eligible applicants may request up to $275,000 in direct costs over a maximum project period of two years, with applications due by June 19, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the detailed announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-177.html.